• Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016
Monday Morning
Skip to content
  • Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016

Tag Archives: John Flannery

GE Healthcare Barges into Cell-Therapy Arena with Swiss Buy; Where’s the FDA?

Steve Walker    July 15, 2016 May 7, 2018    No Comments on GE Healthcare Barges into Cell-Therapy Arena with Swiss Buy; Where’s the FDA?

GE Healthcare (Little Chalfont GBR) just signaled its intention to build a $1 billion business which offers specialized manufacturing tools for an upcoming tidal wave of cell therapies by acquiring… Read more »

Pharmaceuticals    Biosafe Group SA, Cell Stem Cell, Claude Fell, Federal Drug Adminstration, GE Healthcare, JCAR015, John Flannery, Juno Therapeutics Inc., Kieran Murphy, Leigh Turner, Paul Knoepfler, The Economist, The Tufts Center for the Study of Drug Development, University of California, University of Minnesota

Search The Site

Follow @MonMorningNews

Twitter

Tweets by MonMorningNews
Follow me on Blogarama

Facebook

Search The Site

More MondayMorning

  • Recent Posts
  • Most Commented
  • Most Viewed
  • Reducing salt consumption may protect against Alzheimer’s. Considering the stakes, start now.
  • US stock market has a subdued Thanksgiving week, but a slew of healthcare companies rocketed higher.
  • More Chinese medical companies choosing New York over Shanghai, Hong Kong for IPOs; but not always.
  • Health-sector IPO market cools off for Veterans Day breather; but pre-Thanksgiving deals ready to rock.
    • Insys trial opens with tale of sales rep giving lap dance to doctor for fentanyl prescriptions. News organizations seize upon...
    • Voyager Therapeutics signs another neurodegenerative disease deal with AbbVie that screams “Buy this small cap now.”
    • Little known Czech biotech’s cell therapy greatly increases survival in ovarian cancer. Sotio’s potential breakthrough and another pipeline cancer candidate...
    • It’s time to reclassify schizophrenia as a neurologic disorder.
    Copyright 2018
    Ribosome by GalussoThemes.com
    Powered by WordPress